HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Indeed, HDACs inhibitors have a long history of use in psychiatry and neurology as mood stabilizers and anti-epileptics.21,22 Recently, a pan-HDACs inhibitor has been approved by U.S. Food and Drug Administration (FDA) for the treatment of cutaneous T cell lymphoma (CTCL).23 In this study, we investigated the impact of a selective HDAC inhibitor, Trichostatin A (TSA), on human skeletal muscle myoblasts (HSMMs).